Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis
- PMID: 29320995
- PMCID: PMC5763543
- DOI: 10.1186/s12885-017-3934-9
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis
Abstract
Background: Metformin is associated with a reduced risk of some cancers but its effect on prostate cancer is unclear. Some studies suggest only Asians derive this benefit. Therefore, we undertook a systematic review with particular attention to ethnicity.
Methods: Medline, Embase, Scopus, Web of Science, and EBM Reviews were searched from inception to 2015. Two reviewers identified and abstracted articles. Studies were pooled using random effects model and stratified by Western- vs Asian-based populations.
Results: We identified 482 studies; 26 underwent full review. Of Western-based studies (n = 23), two were randomized trials and 21 were observational studies. All Asian-based studies (n = 3) were observational. There were 1,572,307 patients, 1,171,643 Western vs 400,664 Asian. Across all studies there was no association between metformin and prostate cancer (RR: 1.01, 95%CI: 0.86-1.18, I2: 97%), with similar findings in Western-based trials (RR: 1.38, 95%CI: 0.72-2.64 I2: 15%) and observational studies (RR: 1.03 95%CI: 0.94-1.13, I2: 88%). Asian-based studies suggested a non-significant reduction (RR: 0.75, 95%CI: 0.42-1.34, I2: 90%), although these results were highly influenced by one study of almost 400,000 patients (propensity-adjusted RR: 0.47 95%CI 0.45-0.49). Removing this influential study yielded an estimate more congruent with Western-based studies (RR: 0.98 95%CI:0.71-1.36, I2: 0%).
Conclusion: There is likely no association between metformin and risk of prostate cancer, in either Western-based or Asian-based populations after removing a highly influential Asian-based study.
Keywords: Ethnicity & prostate cancer; Metformin.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
Electronic cigarettes for smoking cessation.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 Jan 8;1:CD010216. doi: 10.1002/14651858.CD010216.pub8. PMID: 36384212 Free PMC article. Updated.
-
Electronic cigarettes for smoking cessation.Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Nov 17;11:CD010216. doi: 10.1002/14651858.CD010216.pub7. PMID: 34519354 Free PMC article. Updated.
-
Negative pressure wound therapy for surgical wounds healing by primary closure.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD009261. doi: 10.1002/14651858.CD009261.pub7. Cochrane Database Syst Rev. 2022. PMID: 35471497 Free PMC article.
-
Selenium for preventing cancer.Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4. Cochrane Database Syst Rev. 2018. PMID: 29376219 Free PMC article.
-
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Sep 15;9:CD006332. doi: 10.1002/14651858.CD006332.pub4. PMID: 29869799 Free PMC article. Updated.
Cited by
-
Observation of Efficacy of Internet-Based Chronic Disease Management Model Combined with Modified Therapy of Bushenyiliu Decoction in Treating Patients with Type 2 Diabetes Mellitus and Prostate Cancer and Its Effect on Disease Control Rate.Evid Based Complement Alternat Med. 2021 Sep 9;2021:7767186. doi: 10.1155/2021/7767186. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34539806 Free PMC article.
-
Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2.Thorac Cancer. 2020 Mar;11(3):686-692. doi: 10.1111/1759-7714.13318. Epub 2020 Feb 7. Thorac Cancer. 2020. PMID: 32031335 Free PMC article.
-
Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models.Oncol Lett. 2021 Oct;22(4):715. doi: 10.3892/ol.2021.12976. Epub 2021 Aug 8. Oncol Lett. 2021. Retraction in: Oncol Lett. 2025 May 12;30(1):336. doi: 10.3892/ol.2025.15082. PMID: 34429755 Free PMC article. Retracted.
-
2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.Eur Urol. 2023 Aug;84(2):191-206. doi: 10.1016/j.eururo.2023.04.021. Epub 2023 May 16. Eur Urol. 2023. PMID: 37202314 Free PMC article.
-
Type 2 Diabetes Mellitus and Cancer: Epidemiology, Physiopathology and Prevention.Biomedicines. 2021 Oct 9;9(10):1429. doi: 10.3390/biomedicines9101429. Biomedicines. 2021. PMID: 34680546 Free PMC article. Review.
References
-
- Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151–158. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical